PE20220015A1 - 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresion - Google Patents
5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresionInfo
- Publication number
- PE20220015A1 PE20220015A1 PE2021001360A PE2021001360A PE20220015A1 PE 20220015 A1 PE20220015 A1 PE 20220015A1 PE 2021001360 A PE2021001360 A PE 2021001360A PE 2021001360 A PE2021001360 A PE 2021001360A PE 20220015 A1 PE20220015 A1 PE 20220015A1
- Authority
- PE
- Peru
- Prior art keywords
- disorder
- dimethyltryptamine
- dmt
- meo
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE 5-METOXI-N,N-DIMETILTRIPTAMINA (5-MEO-DMT) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO PARA SU USO EN EL TRATAMIENTO DE UN PACIENTE QUE PADECE UN TRASTORNO MENTAL TAL COMO TRASTORNO DEPRESIVO MAYOR, TRASTORNO DEPRESIVO PERSISTENTE, TRASTORNO DE ANSIEDAD, TRASTORNO DE ESTRES POSTRAUMATICO, TRASTORNO DISMORFICO CORPORAL, TRASTORNO OBSESIVO COMPULSIVO, TRASTORNO ALIMENTARIO Y ABUSO DE SUSTANCIAS PSICOACTIVAS. TAMBIEN SE PROPORCIONAN REGIMENES DE DOSIFICACION PARA TRATAR ESTOS TRASTORNOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19158774 | 2019-02-22 | ||
| PCT/EP2020/054803 WO2020169850A1 (en) | 2019-02-22 | 2020-02-24 | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220015A1 true PE20220015A1 (es) | 2022-01-11 |
Family
ID=65529503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001360A PE20220015A1 (es) | 2019-02-22 | 2020-02-24 | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresion |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20220071958A1 (es) |
| EP (3) | EP4349407B1 (es) |
| JP (2) | JP7598326B2 (es) |
| KR (1) | KR20210154966A (es) |
| CN (1) | CN114555078A (es) |
| AU (1) | AU2020225410B2 (es) |
| BR (1) | BR112021016153A2 (es) |
| CA (1) | CA3130406A1 (es) |
| CL (1) | CL2021002174A1 (es) |
| CO (1) | CO2021010882A2 (es) |
| CR (1) | CR20210437A (es) |
| DK (2) | DK3927337T3 (es) |
| DO (1) | DOP2021000176A (es) |
| EA (1) | EA202192318A1 (es) |
| EC (1) | ECSP21060868A (es) |
| ES (2) | ES3031965T3 (es) |
| FI (2) | FI4349407T3 (es) |
| HR (2) | HRP20250590T1 (es) |
| HU (2) | HUE071841T2 (es) |
| IL (1) | IL285537A (es) |
| LT (2) | LT4349407T (es) |
| MA (1) | MA55021B1 (es) |
| MD (1) | MD3927337T2 (es) |
| MX (2) | MX2021009941A (es) |
| NI (1) | NI202100080A (es) |
| PE (1) | PE20220015A1 (es) |
| PL (2) | PL4349407T3 (es) |
| PT (2) | PT4349407T (es) |
| RS (2) | RS65706B1 (es) |
| SI (2) | SI4349407T1 (es) |
| SM (1) | SMT202400154T1 (es) |
| WO (1) | WO2020169850A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220071958A1 (en) | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (en) * | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| PT3873883T (pt) | 2019-11-07 | 2023-03-24 | Small Pharma Ltd | Método de síntese |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| PH12022553135A1 (en) | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP4595962A3 (en) | 2020-06-12 | 2025-10-22 | Beckley Psytech Limited | Pharmaceutical composition |
| JP7567024B2 (ja) * | 2020-08-05 | 2024-10-15 | ユニヴェルシテートスピタル バーゼル | Ｄｍｔ補助心理療法のための静脈内ｄｍｔ投与方法 |
| EP4200021A1 (en) | 2020-08-18 | 2023-06-28 | Cybin IRL Limited | Therapeutic phenethylamine compositions and methods of use |
| AU2021334933B2 (en) * | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| CA3194558A1 (en) * | 2020-10-02 | 2022-04-07 | Brett J. GREENE | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
| WO2022082058A1 (en) * | 2020-10-16 | 2022-04-21 | Eleusis Therapeutics Us, Inc. | Method of treatment by tryptamine alkaloids |
| WO2022117640A1 (en) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US20220265582A1 (en) * | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
| CA3113414A1 (en) * | 2021-03-29 | 2022-09-29 | Mind Cure Health Inc. | Psychedelics protocol computer systems and methods |
| BR112023022195A2 (pt) | 2021-04-26 | 2024-01-16 | Atai Therapeutics Inc | Novas composições e métodos de n,n-dimetiltriptamina |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| JP2024517194A (ja) * | 2021-05-03 | 2024-04-19 | マインド メディシン， インコーポレイテッド | サイケデリック薬の用量を漸増する方法 |
| WO2022235927A1 (en) * | 2021-05-05 | 2022-11-10 | Gilgamesh Pharmaceuticals, Inc. | Novel tryptamines and methods of treating mood disorders |
| MX2023013928A (es) | 2021-05-25 | 2023-12-08 | Atai Therapeutics Inc | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina. |
| JP2024522174A (ja) | 2021-06-09 | 2024-06-11 | アタイ セラピューティクス， インコーポレイテッド | ジメチルトリプタミンの新規プロドラッグおよびコンジュゲート |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| JP2024540527A (ja) * | 2021-11-18 | 2024-10-31 | サイビン ユーケー リミテッド | 注射製剤及び吸入製剤 |
| US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| EP4499074A1 (en) | 2022-03-27 | 2025-02-05 | GH Research Ireland Limited | 5-meo-dtm for the treatment of bipolar disorder |
| AU2023244452A1 (en) | 2022-03-27 | 2024-11-07 | GH Research Ireland Limited | Treatment of cognitive dysfunction |
| RS65585B1 (sr) | 2022-03-27 | 2024-06-28 | Gh Res Ireland Limited | Kristalna so 5-meo-dmt hidrobromid |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| WO2024160391A1 (en) | 2023-01-30 | 2024-08-08 | GH Research Ireland Limited | Treatment of mental disorders |
| IL322428A (en) | 2023-01-30 | 2025-09-01 | Gh Res Ireland Limited | 5-Methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in nursing mothers |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| WO2024251807A1 (en) * | 2023-06-08 | 2024-12-12 | Cybin Irl Limited | Companion animal treatments |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025068714A1 (en) * | 2023-09-28 | 2025-04-03 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| WO2025087962A1 (en) | 2023-10-23 | 2025-05-01 | Reconnect Labs Ag | Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses |
| WO2025111597A1 (en) * | 2023-11-22 | 2025-05-30 | Gilgamesh Pharmaceuticals, Inc. | A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| JP2007516404A (ja) | 2003-05-21 | 2007-06-21 | アレックザ ファーマシューティカルズ， インコーポレイテッド | 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット |
| ES2355983T3 (es) | 2006-08-01 | 2011-04-01 | STOBI GMBH & CO. KG | Balón de válvula para inhaladores . |
| CN103816150A (zh) * | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| US20220071958A1 (en) | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
-
2020
- 2020-02-24 US US17/431,626 patent/US20220071958A1/en not_active Abandoned
- 2020-02-24 JP JP2021549427A patent/JP7598326B2/ja active Active
- 2020-02-24 LT LTEP24157425.0T patent/LT4349407T/lt unknown
- 2020-02-24 HU HUE24157425A patent/HUE071841T2/hu unknown
- 2020-02-24 EP EP24157425.0A patent/EP4349407B1/en active Active
- 2020-02-24 DK DK20710059.5T patent/DK3927337T3/da active
- 2020-02-24 FI FIEP24157425.0T patent/FI4349407T3/fi active
- 2020-02-24 FI FIEP20710059.5T patent/FI3927337T3/fi active
- 2020-02-24 HR HRP20250590TT patent/HRP20250590T1/hr unknown
- 2020-02-24 RS RS20240531A patent/RS65706B1/sr unknown
- 2020-02-24 MD MDE20211248T patent/MD3927337T2/ro unknown
- 2020-02-24 KR KR1020217030215A patent/KR20210154966A/ko active Pending
- 2020-02-24 CN CN202080030317.3A patent/CN114555078A/zh active Pending
- 2020-02-24 DK DK24157425.0T patent/DK4349407T3/da active
- 2020-02-24 SI SI202030619T patent/SI4349407T1/sl unknown
- 2020-02-24 WO PCT/EP2020/054803 patent/WO2020169850A1/en not_active Ceased
- 2020-02-24 HU HUE20710059A patent/HUE066828T2/hu unknown
- 2020-02-24 PL PL24157425.0T patent/PL4349407T3/pl unknown
- 2020-02-24 PT PT241574250T patent/PT4349407T/pt unknown
- 2020-02-24 RS RS20250591A patent/RS66912B1/sr unknown
- 2020-02-24 EP EP20710059.5A patent/EP3927337B8/en active Active
- 2020-02-24 PT PT207100595T patent/PT3927337T/pt unknown
- 2020-02-24 AU AU2020225410A patent/AU2020225410B2/en active Active
- 2020-02-24 SM SM20240154T patent/SMT202400154T1/it unknown
- 2020-02-24 LT LTEPPCT/EP2020/054803T patent/LT3927337T/lt unknown
- 2020-02-24 CA CA3130406A patent/CA3130406A1/en active Pending
- 2020-02-24 SI SI202030414T patent/SI3927337T1/sl unknown
- 2020-02-24 CR CR20210437A patent/CR20210437A/es unknown
- 2020-02-24 HR HRP20240532TT patent/HRP20240532T1/hr unknown
- 2020-02-24 PL PL20710059.5T patent/PL3927337T3/pl unknown
- 2020-02-24 MX MX2021009941A patent/MX2021009941A/es unknown
- 2020-02-24 BR BR112021016153-8A patent/BR112021016153A2/pt unknown
- 2020-02-24 EP EP24157388.0A patent/EP4353314A3/en active Pending
- 2020-02-24 EA EA202192318A patent/EA202192318A1/ru unknown
- 2020-02-24 ES ES24157425T patent/ES3031965T3/es active Active
- 2020-02-24 MA MA55021A patent/MA55021B1/fr unknown
- 2020-02-24 ES ES20710059T patent/ES2984438T3/es active Active
- 2020-02-24 PE PE2021001360A patent/PE20220015A1/es unknown
-
2021
- 2021-08-11 IL IL285537A patent/IL285537A/en unknown
- 2021-08-16 CL CL2021002174A patent/CL2021002174A1/es unknown
- 2021-08-17 EC ECSENADI202160868A patent/ECSP21060868A/es unknown
- 2021-08-17 MX MX2025002567A patent/MX2025002567A/es unknown
- 2021-08-18 CO CONC2021/0010882A patent/CO2021010882A2/es unknown
- 2021-08-20 NI NI202100080A patent/NI202100080A/es unknown
- 2021-08-20 DO DO2021000176A patent/DOP2021000176A/es unknown
-
2024
- 2024-05-28 US US18/675,614 patent/US20240307350A1/en active Pending
- 2024-11-29 JP JP2024208392A patent/JP2025029035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220015A1 (es) | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresion | |
| CO2021010883A2 (es) | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX390728B (es) | Composicion farmaceutica para usarse en la prevencion y/o tratamiento de enfermedades que se desarrollan o progresan como resultado de una disminucion o perdida de actividad del factor viii de coagulacion sanguinea activado. | |
| NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| NI201800040A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| MX2019011606A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MX2019013893A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MX362804B (es) | Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| CO2022013429A2 (es) | Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma | |
| EA201591603A1 (ru) | Новые терапевтические комбинации миртазапина для применения при болевых расстройствах | |
| MX2022014198A (es) | Usos y formulaciones de los cannabinoides. | |
| CL2025001006A1 (es) | Uso de enavogliflozina para tratar o prevenir nefropatía. | |
| MX2023006855A (es) | Formas de dosificacion y usos terapeuticos de l-4-cloro quinurenina | |
| EA201700155A1 (ru) | Фармацевтическая композиция для лечения туберкулеза |